Drugs Made in America Acquisition Corp. (DMAAU) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Drugs Made in America Acquisition Corp. (DMAAU:NASDAQ), powered by AI.

Current Price
$11.32
Sector
Financial Services
What is the Drugs Made in America Acquisition Corp. stock price forecast?

Drugs Made in America Acquisition Corp. is currently trading at $11.32. View real-time AI analysis on Alpha Lenz.

What is Drugs Made in America Acquisition Corp. insider trading activity?

View the latest insider trading data for Drugs Made in America Acquisition Corp. on Alpha Lenz.

What is Drugs Made in America Acquisition Corp.'s P/E ratio?

View Drugs Made in America Acquisition Corp.'s valuation metrics on Alpha Lenz.

Drugs Made in America Acquisition Corp.

NASDAQ · DMAAU
$11.32+0.00(+0.00%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Drugs Made in America Acquisition Corp.'s future dividend policy...
Alpha Chat Insight

Drugs Made in America Acquisition Corp.'s ROE is 5.1%. Explore profitability and growth together.

Ask for details

Company Overview

Drugs Made in America Acquisition Corp. is a special purpose acquisition company (SPAC) focused on identifying and acquiring businesses predominantly within the pharmaceutical and healthcare sectors. As a SPAC, its primary function is to raise capital through an initial public offering (IPO) with the intent to eventually merge with or acquire an existing company, bringing it public in a streamlined manner. Notable for its emphasis on domestic pharmaceutical manufacturing, Drugs Made in America Acquisition Corp. targets industries that may benefit from increased onshore production and reduced reliance on foreign supply chains. The company plays a significant role in the financial market by providing investors a vehicle to support the growth and resilience of the U.S. pharmaceutical industry, which is critical in addressing national health security and supply chain challenges. By facilitating capital access for burgeoning or transitioning healthcare companies, it helps drive innovation and economic stability within the national context.

CEOMs. Lynn Stockwell
SectorFinancial Services
IndustryShell Companies
0

Company Statistics

FY 2025

Profile

N/AMarket Cap
$0.00Revenue
0.00Shares Out
0Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

4.94%ROA
5.11%ROE
-2.34%ROIC

Financial Health

$6.14KCash & Cash Equivalents
$7.27MNet Debt
3.13%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Drugs Made in America Acquisition Corp. (ticker: DMAAU) is a company listed on NASDAQ in the Financial Services sector (Shell Companies).

The current price is $11.32 with a P/E ratio of -x and P/B of -x.

ROE is 5.11%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Drugs Made in America Acquisition Corp. (DMAAU) Stock Forecast 2026 $11.32 — Price, Financials & Analyst Targets | Alpha Lenz